documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
- perpetual_docket
- 1 = a standing/perpetual docket carrying a sentinel comment-end date (2050 or later; in practice 2099/2100 — agency guidance and exemption dockets that never close). 0 = an ordinary docket with a real deadline. NULL = no end date reported. The site's Open-for-Comment surface EXCLUDES perpetual_docket = 1 by default, so the site count and the bulk dump answer the same question differently: the dump is complete and includes them.
- comment_end_date
- The comment deadline as an Eastern (America/New_York) calendar date — CORRECTED in the 2026-09-06 daily snapshot (DataDawn queue #498): a snapshot whose _metadata row comment_end_date_grain reads 'eastern' carries the Eastern date; the pre-correction snapshots (through 2026-09-05) held the UTC-rolled day, one day LATE on every end-of-day close. Federal comment periods close at 11:59:59 PM Eastern and the source publishes that instant in UTC ('2026-08-26T03:59:59Z' = the 2026-08-25 deadline). Prefer comment_end_datetime for any arithmetic and convert it to America/New_York yourself; never 'subtract a day' from this column.
- comment_end_datetime
- AUTHORITATIVE. The full UTC instant of the comment deadline ('2026-08-26 03:59:59' == 11:59:59 PM Eastern on 2026-08-25). Convert to America/New_York for the official date; prefer this column over comment_end_date for anything computed.
69 rows where agency_id = "FDA" and document_type = "Other" sorted by comment_end_datetime descending
This data as json, CSV (advanced)
agency_id 1
- FDA · 69 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | comment_end_datetime ▲ | perpetual_docket | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-N-7864-0001 | FDA | FDA-2026-N-7864 | Data Request (DR001): Use of the pH Cycling Test Model as a Testing Procedure for Fluoride Dentifrice Drug Products in Over-the-Counter (OTC) Monograph M021: Anticaries Drug Products for Over-the-Counter Human Use | Other | Request | 2026-07-28 | 2026 | 7 | 2026-07-28 | 2027-01-25 | 2027-01-26 04:59:59 | 0 | 2026-07-28 16:50:16 | 1 | 0 | 09000064b93c7444 | |
| FDA-2026-D-8693-0002 | FDA | FDA-2026-D-8693 | Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Guidance for Industry; Draft Guidance for Industry | Other | Guidance | 2026-09-02 | 2026 | 9 | 2026-09-02 | 2026-12-01 | 2026-12-02 04:59:59 | 0 | 2026-09-03 00:56:30 | 1 | 0 | 09000064b94bc729 | |
| FDA-2012-N-1021-0107 | FDA | FDA-2012-N-1021 | Instructions for Submitting Comments on the CDRH Fiscal Year 2027 Proposed Guidance Development | Other | Additional Information | 2026-10-01 | 2026 | 10 | 2026-10-01 | 2026-11-30 | 2026-12-01 04:59:59 | 0 | 2026-10-10 09:00:58 | 1 | 0 | 09000064b95fb842 | |
| FDA-2018-D-4533-2364 | FDA | FDA-2018-D-4533 | Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities; Draft Guidance | Other | Guidance | 2026-08-28 | 2026 | 8 | 2026-08-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-10-06 09:00:30 | 1 | 0 | 09000064b94a6e26 | |
| FDA-2026-P-5995-0001 | FDA | FDA-2026-P-5995 | Suitability Petition from Hyman, Phelps, & McNamara P.C. | Other | Petition(s) | 2026-05-28 | 2026 | 5 | 2026-05-28 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-09-29 15:44:43 | 1 | 0 | 09000064b92f59e1 | |
| FDA-2026-N-9505-0002 | FDA | FDA-2026-N-9505 | Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance | Other | Guidance | 2026-09-25 | 2026 | 9 | 2026-09-25 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-10-13 09:01:01 | 1 | 0 | 09000064b95c6e19 | |
| FDA-2026-N-8563-0001 | FDA | FDA-2026-N-8563 | Regulatory Science Innovations Catalyzing Medical Device Development_Co-sponsored Public Meeting | Other | Meeting | 2026-08-06 | 2026 | 8 | 2026-08-06 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-10-14 09:00:37 | 1 | 0 | 09000064b940e756 | |
| FDA-2025-D-6952-0002 | FDA | FDA-2025-D-6952 | Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants: Guidance for Industry - Draft Guidance | Other | Guidance | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-11-23 | 2026-11-24 04:59:59 | 0 | 2026-10-14 09:01:00 | 1 | 0 | 09000064b96574d6 | |
| FDA-2026-D-8561-0002 | FDA | FDA-2026-D-8561 | Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry | Other | Guidance | 2026-08-20 | 2026 | 8 | 2026-08-20 | 2026-11-18 | 2026-11-19 04:59:59 | 0 | 2026-08-20 17:59:44 | 1 | 0 | 09000064b946ee4d | |
| FDA-2026-D-9429-0002 | FDA | FDA-2026-D-9429 | Electronic Submission Template for Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff - Draft Guidance | Other | Guidance | 2026-09-18 | 2026 | 9 | 2026-09-18 | 2026-11-17 | 2026-11-18 04:59:59 | 0 | 2026-09-18 18:06:45 | 1 | 0 | 09000064b95876d8 | |
| FDA-2025-N-2787-0008 | FDA | FDA-2025-N-2787 | BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy Document | Other | Request | 2026-09-18 | 2026 | 9 | 2026-09-18 | 2026-11-17 | 2026-11-18 04:59:59 | 0 | 2026-09-25 09:00:32 | 1 | 0 | 09000064b9592e12 | |
| FDA-2026-D-7233-0002 | FDA | FDA-2026-D-7233 | Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products VICH GL62; Guidance for Industry (GFI) #298 - Draft Guidance | Other | Guidance | 2026-09-18 | 2026 | 9 | 2026-09-18 | 2026-11-17 | 2026-11-18 04:59:59 | 0 | 2026-09-25 09:00:32 | 1 | 0 | 09000064b958e85f | |
| FDA-2026-N-7914-0001 | FDA | FDA-2026-N-7914 | Public Meeting on Listeria monocytogenes Prevention | Other | Additional Information | 2026-08-03 | 2026 | 8 | 2026-08-03 | 2026-11-02 | 2026-11-03 04:59:59 | 0 | 2026-08-19 09:01:12 | 1 | 0 | 09000064b93e5b66 | |
| FDA-2007-D-0369-2652 | FDA | FDA-2007-D-0369 | PSG_020816 - Draft Guidance on Brinzolamide | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:08:40 | 1 | 0 | 09000064b9470607 | |
| FDA-2007-D-0369-2653 | FDA | FDA-2007-D-0369 | PSG_020732 - Draft Guidance on Buprenorphine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:08:45 | 1 | 0 | 09000064b94706ae | |
| FDA-2007-D-0369-2654 | FDA | FDA-2007-D-0369 | PSG_204370 - Draft Guidance on Cariprazine Hydrochloride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:08:55 | 1 | 0 | 09000064b94706b0 | |
| FDA-2007-D-0369-2655 | FDA | FDA-2007-D-0369 | PSG_050600 - Draft Guidance on Clindamycin Phosphate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:04 | 1 | 0 | 09000064b94706b2 | |
| FDA-2007-D-0369-2656 | FDA | FDA-2007-D-0369 | PSG_215425 - Draft Guidance on Epinephrine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:08 | 1 | 0 | 09000064b94706b4 | |
| FDA-2007-D-0369-2657 | FDA | FDA-2007-D-0369 | PSG_218475 - Draft Guidance on Epinephrine Bitartrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:13 | 1 | 0 | 09000064b94706b6 | |
| FDA-2007-D-0369-2658 | FDA | FDA-2007-D-0369 | PSG_203565 - Draft Guidance on Ferric Carboxymaltose | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:18 | 1 | 0 | 09000064b94706b8 | |
| FDA-2007-D-0369-2659 | FDA | FDA-2007-D-0369 | PSG_022180 - Draft Guidance on Ferumoxytol | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:23 | 1 | 0 | 09000064b94706ba | |
| FDA-2007-D-0369-2660 | FDA | FDA-2007-D-0369 | PSG_020243 - Draft Guidance on Fluvoxamine Maleate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:28 | 1 | 0 | 09000064b94706bc | |
| FDA-2007-D-0369-2661 | FDA | FDA-2007-D-0369 | PSG_020496 - Draft Guidance on Glimepiride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:33 | 1 | 0 | 09000064b94706be | |
| FDA-2007-D-0369-2662 | FDA | FDA-2007-D-0369 | PSG_213876 - Draft Guidance on Hydrocortisone | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:38 | 1 | 0 | 09000064b94706c0 | |
| FDA-2007-D-0369-2663 | FDA | FDA-2007-D-0369 | PSG_206185 - Draft Guidance on Latanoprost | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:09:42 | 1 | 0 | 09000064b94706c2 | |
| FDA-2007-D-0369-2664 | FDA | FDA-2007-D-0369 | PSG_209939 - Draft Guidance on Letermovir | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:09 | 1 | 0 | 09000064b94706c4 | |
| FDA-2007-D-0369-2665 | FDA | FDA-2007-D-0369 | PSG_021343 - Draft Guidance on Leuprolide Acetate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:14 | 1 | 0 | 09000064b94706c6 | |
| FDA-2007-D-0369-2666 | FDA | FDA-2007-D-0369 | PSG_021379 - Draft Guidance on Leuprolide Acetate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:19 | 1 | 0 | 09000064b94706c8 | |
| FDA-2007-D-0369-2667 | FDA | FDA-2007-D-0369 | PSG_021731 - Draft Guidance on Leuprolide Acetate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:24 | 1 | 0 | 09000064b94706ca | |
| FDA-2007-D-0369-2668 | FDA | FDA-2007-D-0369 | PSG_021924 - Draft Guidance on Levothyroxine Sodium | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:29 | 1 | 0 | 09000064b94706cc | |
| FDA-2007-D-0369-2669 | FDA | FDA-2007-D-0369 | PSG_215029 - Draft Guidance on Lidocaine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:35 | 1 | 0 | 09000064b94706ce | |
| FDA-2007-D-0369-2670 | FDA | FDA-2007-D-0369 | PSG_021977 - Draft Guidance on Lisdexamfetamine Dimesylate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:41 | 1 | 0 | 09000064b94706d0 | |
| FDA-2007-D-0369-2671 | FDA | FDA-2007-D-0369 | PSG_219847 - Draft Guidance on Lisdexamfetamine Dimesylate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:46 | 1 | 0 | 09000064b94706d2 | |
| FDA-2007-D-0369-2672 | FDA | FDA-2007-D-0369 | PSG_219485 - Draft Guidance on Maralixibat Chloride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:10:51 | 1 | 0 | 09000064b94706d4 | |
| FDA-2007-D-0369-2673 | FDA | FDA-2007-D-0369 | PSG_214662 - Draft Guidance on Maralixibat Chloride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:06 | 1 | 0 | 09000064b94706d6 | |
| FDA-2007-D-0369-2674 | FDA | FDA-2007-D-0369 | PSG_217593 - Draft Guidance on Meloxicam | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:11 | 1 | 0 | 09000064b94706d8 | |
| FDA-2007-D-0369-2675 | FDA | FDA-2007-D-0369 | PSG_218395 - Draft Guidance on Meloxicam | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:15 | 1 | 0 | 09000064b94706da | |
| FDA-2007-D-0369-2676 | FDA | FDA-2007-D-0369 | PSG_215211 - Draft Guidance on Miglustat | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:20 | 1 | 0 | 09000064b94706dc | |
| FDA-2007-D-0369-2677 | FDA | FDA-2007-D-0369 | PSG_020415 - Draft Guidance on Mirtazapine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:25 | 1 | 0 | 09000064b94706de | |
| FDA-2007-D-0369-2678 | FDA | FDA-2007-D-0369 | PSG_215793 - Draft Guidance on Mitomycin | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:30 | 1 | 0 | 09000064b94706e0 | |
| FDA-2007-D-0369-2679 | FDA | FDA-2007-D-0369 | PSG_203340 - Draft Guidance on Nimodipine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:34 | 1 | 0 | 09000064b94706e2 | |
| FDA-2007-D-0369-2680 | FDA | FDA-2007-D-0369 | PSG_021008 - Draft Guidance on Octreotide Acetate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:40 | 1 | 0 | 09000064b9470826 | |
| FDA-2007-D-0369-2681 | FDA | FDA-2007-D-0369 | PSG_208558 - Draft Guidance on Olaparib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:45 | 1 | 0 | 09000064b9470828 | |
| FDA-2007-D-0369-2683 | FDA | FDA-2007-D-0369 | PSG_020781 - Draft Guidance on Ondansetron | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:11:55 | 1 | 0 | 09000064b947082c | |
| FDA-2007-D-0369-2684 | FDA | FDA-2007-D-0369 | PSG_211150 - Draft Guidance on Pitolisant Hydrochloride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:15 | 1 | 0 | 09000064b947082e | |
| FDA-2007-D-0369-2685 | FDA | FDA-2007-D-0369 | PSG_219685 - Draft Guidance on Rilzabrutinib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:21 | 1 | 0 | 09000064b9470830 | |
| FDA-2007-D-0369-2686 | FDA | FDA-2007-D-0369 | PSG_219301 - Draft Guidance on Sebetralstat | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:25 | 1 | 0 | 09000064b9470832 | |
| FDA-2007-D-0369-2687 | FDA | FDA-2007-D-0369 | PSG_020573 - Draft Guidance on Sodium Phenylbutyrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:30 | 1 | 0 | 09000064b9470834 | |
| FDA-2007-D-0369-2688 | FDA | FDA-2007-D-0369 | PSG_214860 - Draft Guidance on Sodium Phenylbutyrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:41 | 1 | 0 | 09000064b9470836 | |
| FDA-2007-D-0369-2689 | FDA | FDA-2007-D-0369 | PSG_219839 - Draft Guidance on Sunvozertinib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:46 | 1 | 0 | 09000064b9470838 | |
| FDA-2007-D-0369-2690 | FDA | FDA-2007-D-0369 | PSG_219713 - Draft Guidance on Taletrectinib Adipate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:51 | 1 | 0 | 09000064b947083a | |
| FDA-2007-D-0369-2691 | FDA | FDA-2007-D-0369 | PSG_211801 - Draft Guidance on Tenapanor Hydrochloride | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:12:55 | 1 | 0 | 09000064b947083d | |
| FDA-2007-D-0369-2692 | FDA | FDA-2007-D-0369 | PSG_219304 - Draft Guidance on Vimseltinib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:13:07 | 1 | 0 | 09000064b947083f | |
| FDA-2007-D-0369-2693 | FDA | FDA-2007-D-0369 | PSG_021774 - Draft Guidance on Zolpidem Tartrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:13:14 | 1 | 0 | 09000064b9470841 | |
| FDA-2007-D-0369-2694 | FDA | FDA-2007-D-0369 | PSG_021997 - Draft Guidance on Zolpidem Tartrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:13:19 | 1 | 0 | 09000064b9470843 | |
| FDA-2007-D-0369-2695 | FDA | FDA-2007-D-0369 | PSG_022328 - Draft Guidance on Zolpidem Tartrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-08-24 20:13:25 | 1 | 0 | 09000064b9470845 | |
| FDA-2007-D-0369-2651 | FDA | FDA-2007-D-0369 | PSG_204251 - Draft Guidance on Brimonidine Tartrate; Brinzolamide | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:16 | 1 | 0 | 09000064b9470605 | |
| FDA-2007-D-0369-2650 | FDA | FDA-2007-D-0369 | PSG_217673 - Draft Guidance on Brensocatib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:21 | 1 | 0 | 09000064b9470603 | |
| FDA-2007-D-0369-2649 | FDA | FDA-2007-D-0369 | PSG_217729 - Draft Guidance on Bosutinib Monohydrate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:28 | 1 | 0 | 09000064b9470601 | |
| FDA-2007-D-0369-2648 | FDA | FDA-2007-D-0369 | PSG_217307 - Draft Guidance on Bimatoprost | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:33 | 1 | 0 | 09000064b94705ff | |
| FDA-2007-D-0369-2647 | FDA | FDA-2007-D-0369 | PSG_214902 - Draft Guidance on Benzoyl Peroxide; Tretinoin | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:38 | 1 | 0 | 09000064b94705fd | |
| FDA-2007-D-0369-2645 | FDA | FDA-2007-D-0369 | PSG_207924 - Draft Guidance on Baricitinib | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:48 | 1 | 0 | 09000064b94705f9 | |
| FDA-2007-D-0369-2644 | FDA | FDA-2007-D-0369 | PSG_219696 - Draft Guidance on Avatrombopag Maleate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:51:56 | 1 | 0 | 09000064b94705f7 | |
| FDA-2007-D-0369-2643 | FDA | FDA-2007-D-0369 | PSG_210526 - Draft Guidance on Amphetamine;Amphetamine Aspartate/Dextroamphetamine Sulfate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:52:01 | 1 | 0 | 09000064b94705f5 | |
| FDA-2007-D-0369-2642 | FDA | FDA-2007-D-0369 | PSG_208147 - Draft Guidance on Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:52:06 | 1 | 0 | 09000064b94705f3 | |
| FDA-2007-D-0369-2641 | FDA | FDA-2007-D-0369 | PSG_204325 - Draft Guidance on Amphetamine | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:52:11 | 1 | 0 | 09000064b94705f1 | |
| FDA-2007-D-0369-2646 | FDA | FDA-2007-D-0369 | PSG_214510 - Draft Guidance on Benzoyl Peroxide | Other | Guidance | 2026-08-24 | 2026 | 8 | 2026-08-24 | 2026-10-23 | 2026-10-24 03:59:59 | 0 | 2026-09-29 20:52:49 | 1 | 0 | 09000064b94705fb | |
| FDA-2017-D-5974-0013 | FDA | FDA-2017-D-5974 | Determining Whether to Submit an ANDA or a 505(b)(2) Application; Guidance for Industry; Draft Guidance | Other | Guidance | 2026-08-18 | 2026 | 8 | 2026-08-18 | 2026-10-19 | 2026-10-20 03:59:59 | 0 | 2026-09-27 09:00:23 | 1 | 0 | 09000064b9467762 | |
| FDA-2026-N-7874-0001 | FDA | FDA-2026-N-7874 | Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback | Other | Request | 2026-08-18 | 2026 | 8 | 2026-08-18 | 2026-10-19 | 2026-10-20 03:59:59 | 0 | 2026-10-15 09:00:27 | 1 | 0 | 09000064b9467189 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT,
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT, -- EASTERN calendar date of the close (queue #498 writer
-- fix, 2026-09-05; was the UTC-rolled day AFTER the ET
-- deadline before that). Display-grade only.
comment_end_datetime TEXT, -- full UTC close ("YYYY-MM-DD HH:MM:SS", queue #498):
-- the API expresses the 11:59:59 PM ET deadline as a UTC
-- datetime. AUTHORITATIVE: the predicate, days_left and
-- any timezone-aware render derive from THIS column.
perpetual_docket INTEGER, -- 1 = sentinel end date (queue #464); NULL = no end date
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
CREATE INDEX idx_docs_perpetual ON documents(perpetual_docket);
document_type 1